Ultragenyx Pharmaceutical (RARE) said Thursday the first patient has been dosed in the phase 3 study of its drug candidate GTX-102 for the treatment of Angelman syndrome, a rare neurodegenerative disorder.
The company said it intends to enroll about 120 children in the Aspire study to evaluate the efficacy and safety of GTX-102.
Ultragenyx also said it is on track to start the Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and in other age groups in 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.